HAYWARD, Calif. -- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced the departure of its Chief Operations Officer Jennifer Jarrett, effective March 30, to pursue a CEO opportunity outside of Arcus.
“Jen has been instrumental in the growth of Arcus from a nascent start-up with early research programs to a thriving biotech company with several programs in late-stage development and Phase 3 readouts over the next 12-24 months,” said Terry Rosen, Ph.D., chief executive officer of Arcus. “Arcus is in an exceptional position to maximize the opportunities within our portfolio, including our emerging immunology and inflammation development candidates, two of which are expected to enter the clinic over the coming year and casdatifan, a best-in-class HIF-2a inhibitor and potential future standard of care in the treatment of kidney cancer. We look forward to sharing a steady stream of data over the next year that will further build upon the strong momentum and enthusiasm for the casdatifan development program. We thank Jen for her contributions and wish her continued success in her new role.”
Arcus has a strong and deeply experienced leadership team and does not plan to seek a replacement for the COO role.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for the treatment of cancer and inflammatory and autoimmune diseases. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of its late-stage portfolio of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Forward-Looking Statements
This statement contains forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the timing of Phase 3 readouts and future disclosures of data from the company’s casdatifan program, and the potential and opportunities for the company’s portfolio of investigational molecules, including casdatifan. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, risks associated with: uncertainties in timelines associated with the conduct of clinical studies due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or supplying product for such clinical trials, including PEAK-1; unfavorable global economic, political and trade conditions; and unexpected emergence of adverse events or other undesirable side effects with casdatifan. Risks and uncertainties facing Arcus are described more fully in the “Risk Factors” section of Arcus’s most recent periodic report filed with the U.S. Securities and Exchange Commission (SEC) and in other filings that Arcus makes with the SEC from time to time, which are available at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this disclosure. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release, except to the extent required by law.
Investor and Media Inquiries:
Holli Kolkey
VP of Corporate Affairs
(650) 922-1269
hkolkey@arcusbio.com
Maryam Bassiri
Director, Corporate Affairs
(510) 406-8520
mbassiri@arcusbio.com